{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:33:54Z","timestamp":1794612834705,"version":"4.9.1"},"reference-count":65,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec id=\"ab-coi240005-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of PSA for high-grade PCa (ie, grade group [GG] 2 or greater).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240005-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop a multiplex urinary panel for high-grade PCa and validate its external performance relative to current guideline-endorsed biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240005-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>RNA sequencing analysis of 58\u202f724 genes identified 54 markers of PCa, including 17 markers uniquely overexpressed by high-grade cancers. Gene expression and clinical factors were modeled in a new urinary test for high-grade PCa (MyProstateScore 2.0 [MPS2]). Optimal models were developed in parallel without prostate volume (MPS2) and with prostate volume (MPS2+). The locked models underwent blinded external validation in a prospective National Cancer Institute trial cohort. Data were collected from January 2008 to December 2020, and data were analyzed from November 2022 to November 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240005-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Protocolized blood and urine collection and transrectal ultrasound-guided systematic prostate biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240005-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Multiple biomarker tests were assessed in the validation cohort, including serum PSA alone, the Prostate Cancer Prevention Trial risk calculator, and the Prostate Health Index (PHI) as well as derived multiplex 2-gene and 3-gene models, the original 2-gene MPS test, and the 18-gene MPS2 models. Under a testing approach with 95% sensitivity for PCa of GG 2 or greater, measures of diagnostic accuracy and clinical consequences of testing were calculated. Cancers of GG 3 or greater were assessed secondarily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240005-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 761 men included in the development cohort, the median (IQR) age was 63 (58-68) years, and the median (IQR) PSA level was 5.6 (4.6-7.2) ng\/mL; of 743 men included in the validation cohort, the median (IQR) age was 62 (57-68) years, and the median (IQR) PSA level was 5.6 (4.1-8.0) ng\/mL. In the validation cohort, 151 (20.3%) had high-grade PCa on biopsy. Area under the receiver operating characteristic curve values were 0.60 using PSA alone, 0.66 using the risk calculator, 0.77 using PHI, 0.76 using the derived multiplex 2-gene model, 0.72 using the derived multiplex 3-gene model, and 0.74 using the original MPS model compared with 0.81 using the MPS2 model and 0.82 using the MPS2+ model. At 95% sensitivity, the MPS2 model would have reduced unnecessary biopsies performed in the initial biopsy population (range for other tests, 15% to 30%; range for MPS2, 35% to 42%) and repeat biopsy population (range for other tests, 9% to 21%; range for MPS2, 46% to 51%). Across pertinent subgroups, the MPS2 models had negative predictive values of 95% to 99% for cancers of GG 2 or greater and of 99% for cancers of GG 3 or greater.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240005-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this study, a new 18-gene PCa test had higher diagnostic accuracy for high-grade PCa relative to existing biomarker tests. Clinically, use of this test would have meaningfully reduced unnecessary biopsies performed while maintaining highly sensitive detection of high-grade cancers. These data support use of this new PCa biomarker test in patients with elevated PSA levels to reduce the potential harms of PCa screening while preserving its long-term benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.0455","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:01:49Z","timestamp":1713438109000},"page":"726","source":"Crossref","is-referenced-by-count":70,"title":["Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer"],"prefix":"10.1001","volume":"10","author":[{"given":"Jeffrey J.","family":"Tosoian","sequence":"first","affiliation":[{"name":"Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanbo","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan L.","family":"Samora","sequence":"additional","affiliation":[{"name":"Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashar S.","family":"Niknafs","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoey","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Herron","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Vaishampayan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter S.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Arivoli","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Trock","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh S.","family":"Palapattu","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simpa S.","family":"Salami","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi P.","family":"Kunju","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Tomlins","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"},{"name":"Strata Oncology, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Sokoll","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziding","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Sanda","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingye","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"},{"name":"Department of Urology, University of Michigan, Ann Arbor"},{"name":"Howard Hughes Medical Institute, Chevy Chase, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EDRN-PCA3 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bidair","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kibel","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Partin","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Taneja","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Howard","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith M.","family":"Regan","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Groskopf","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chipman","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dattatraya H.","family":"Patil","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Scherr","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kagan","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fan","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron Y.","family":"Joon","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas E.","family":"Bantis","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rubin","sequence":"additional","affiliation":[{"name":"for the EDRN-PCA3 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi240005r1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi240005r2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer.","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"coi240005r3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of followup in the G\u00f6teborg randomized population-based prostate cancer screening trial.","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"J Urol"},{"issue":"18","key":"coi240005r4","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force.","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"coi240005r6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part i: prostate cancer screening.","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"issue":"10","key":"coi240005r7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis.","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"coi240005r8","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003336.01","article-title":"PD38-01 Negative predictive value of prostate MRI in real world practice: results from a statewide surgical collaboration.","volume":"209","author":"Zhu","year":"2023","journal-title":"J Urol"},{"issue":"3","key":"coi240005r9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","article-title":"Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis.","volume":"78","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"coi240005r10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.euf.2017.11.010","article-title":"Prostate magnetic resonance imaging interpretation varies substantially across radiologists.","volume":"5","author":"Sonn","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"8","key":"coi240005r11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jval.2021.02.009","article-title":"Economic evaluation of urine-based or magnetic resonance imaging reflex tests in men with intermediate prostate-specific antigen levels in the United States.","volume":"24","author":"Jiao","year":"2021","journal-title":"Value Health"},{"issue":"7","key":"coi240005r12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jnci\/djac066","article-title":"Grade migration of prostate cancer in the United States during the last decade.","volume":"114","author":"Borregales","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"coi240005r13","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.21037\/tau","article-title":"Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions.","volume":"10","author":"Eyrich","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"4","key":"coi240005r14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer.","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"issue":"7637","key":"coi240005r15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer.","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"issue":"8","key":"coi240005r16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/nbt.1914","article-title":"Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.","volume":"29","author":"Prensner","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"3","key":"coi240005r17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.3192","article-title":"The landscape of long noncoding RNAs in the human transcriptome.","volume":"47","author":"Iyer","year":"2015","journal-title":"Nat Genet"},{"key":"coi240005r18","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"coi240005r19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","article-title":"Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment.","volume":"70","author":"Tomlins","year":"2016","journal-title":"Eur Urol"},{"issue":"36","key":"coi240005r20","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi240005r21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi240005r22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.juro.2012.12.108","article-title":"The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.","volume":"190","author":"Ankerst","year":"2013","journal-title":"J Urol"},{"issue":"2","key":"coi240005r23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00345-011-0804-y","article-title":"Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the Prostate Biopsy Collaborative Group.","volume":"30","author":"Roobol","year":"2012","journal-title":"World J Urol"},{"issue":"28","key":"coi240005r24","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1002\/sim.v36.28","article-title":"A closed testing procedure to select an appropriate method for updating prediction models.","volume":"36","author":"Vergouwe","year":"2017","journal-title":"Stat Med"},{"issue":"1","key":"coi240005r25","doi-asserted-by":"publisher","first-page":"W1-73","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"issue":"21","key":"coi240005r26","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/cncr.v128.21","article-title":"Racial disparities in Black men with prostate cancer: a literature review.","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"coi240005r27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.amjsurg.2023.05.011","article-title":"The accuracy of race & ethnicity data in US based healthcare databases: a systematic review.","volume":"226","author":"Johnson","year":"2023","journal-title":"Am J Surg"},{"issue":"8","key":"coi240005r28","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamaoncol.2017.0177","article-title":"Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer.","volume":"3","author":"Sanda","year":"2017","journal-title":"JAMA Oncol"},{"key":"coi240005r29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves.","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"coi240005r30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/JU.0000000000001430","article-title":"Use of the MyProstateScore Test to rule out clinically significant cancer: validation of a straightforward clinical testing approach.","volume":"205","author":"Tosoian","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"coi240005r31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.juro.2015.01.091","article-title":"Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy na\u00efve men.","volume":"194","author":"de la Calle","year":"2015","journal-title":"J Urol"},{"issue":"7","key":"coi240005r32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy.","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"coi240005r33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"coi240005r34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"The Prostate Health Index selectively identifies clinically significant prostate cancer.","volume":"193","author":"Loeb","year":"2015","journal-title":"J Urol"},{"issue":"2","key":"coi240005r35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000000293","article-title":"Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer before initial prostate biopsy.","volume":"202","author":"Haese","year":"2019","journal-title":"J Urol"},{"issue":"3","key":"coi240005r36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology.","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"coi240005r38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","article-title":"Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer.","volume":"68","author":"Nordstr\u00f6m","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"coi240005r39","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.juro.2015.12.079","article-title":"More favorable pathological outcomes in men with low risk prostate cancer diagnosed on repeat versus initial transrectal ultrasound guided prostate biopsy.","volume":"195","author":"ElShafei","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"coi240005r41","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.juro.2008.06.022","article-title":"Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.","volume":"180","author":"Tan","year":"2008","journal-title":"J Urol"},{"key":"coi240005r42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","article-title":"A simple, step-by-step guide to interpreting decision curve analysis.","volume":"3","author":"Vickers","year":"2019","journal-title":"Diagn Progn Res"},{"key":"coi240005r43","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1136\/bmj.i6","article-title":"Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.","volume":"352","author":"Vickers","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"coi240005r45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00345-019-02759-x","article-title":"A critical appraisal of biomarkers in prostate cancer.","volume":"38","author":"Narayan","year":"2020","journal-title":"World J Urol"},{"issue":"12","key":"coi240005r46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw165","article-title":"Repeat prostate-specific antigen tests before prostate biopsy decisions.","volume":"108","author":"Nordstr\u00f6m","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi240005r47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12894-020-00712-4","article-title":"A urine-based exosomal gene expression test stratifies risk of high-grade prostate cancer in men with prior negative prostate biopsy undergoing repeat biopsy.","volume":"20","author":"McKiernan","year":"2020","journal-title":"BMC Urol"},{"issue":"3","key":"coi240005r48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.21203\/rs.3.rs-1728404\/v1","article-title":"MyProstateScore in men considering repeat biopsy: validation of a simple testing approach.","volume":"26","author":"Tosoian","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"coi240005r51","doi-asserted-by":"publisher","first-page":"729.e1","DOI":"10.1016\/j.urolonc.2021.02.018","article-title":"Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients.","volume":"39","author":"Bloom","year":"2021","journal-title":"Urol Oncol"},{"issue":"5","key":"coi240005r52","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.juro.2008.01.013","article-title":"PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.","volume":"179","author":"Nakanishi","year":"2008","journal-title":"J Urol"},{"issue":"13","key":"coi240005r53","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/S1470-2045(14)71113-1","article-title":"RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.","volume":"15","author":"Prensner","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi240005r54","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1309\/AJCPU7PPWUPYG8OH","article-title":"Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.","volume":"138","author":"Young","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"coi240005r55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1200\/jco.2016.34.2_suppl.31","article-title":"Elevated HOXC6\/DLX1 mRNA biomarker levels in urine to help select patients at increased risk for high-grade prostate cancer detection upon prostate biopsy.","volume":"34","author":"Hendriks","year":"2016","journal-title":"J Clin Oncol"},{"key":"coi240005r56","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00054","article-title":"Biologic significance of magnetic resonance imaging invisibility in localized prostate cancer.","volume":"3","author":"Salami","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"coi240005r57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"issue":"21","key":"coi240005r58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123468","article-title":"Transcriptomic heterogeneity in multifocal prostate cancer.","volume":"3","author":"Salami","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"coi240005r59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","article-title":"Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators.","volume":"71","author":"Wei","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"coi240005r60","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bju.2010.105.issue-3","article-title":"A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.","volume":"105","author":"Moussa","year":"2010","journal-title":"BJU Int"},{"issue":"5","key":"coi240005r61","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","article-title":"Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.","volume":"61","author":"Epstein","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"coi240005r62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12894-019-0526-9","article-title":"Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry.","volume":"19","author":"Bullock","year":"2019","journal-title":"BMC Urol"},{"issue":"3","key":"coi240005r63","doi-asserted-by":"publisher","DOI":"10.2196\/30430","article-title":"Prostate cancer risk calculators for healthy populations: systematic review.","volume":"7","author":"Bandala-Jacques","year":"2021","journal-title":"JMIR Cancer"},{"issue":"2","key":"coi240005r64","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","article-title":"A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts.","volume":"74","author":"Ankerst","year":"2018","journal-title":"Eur Urol"},{"key":"coi240005r40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-319-78646-9_3","volume-title":"Prostate Cancer: Clinical Case Scenarios","author":"Kearns","year":"2018"},{"key":"coi240005r5","unstructured":"National Comprehensive Cancer Network. Prostate cancer early detection (version 1.2023). Accessed May 19, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf"},{"key":"coi240005r37","unstructured":"US Centers for Medicare & Medicaid Services. Biomarker testing for prostate cancer diagnosis. Accessed March 23, 2020. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?LCDId=37733"},{"key":"coi240005r44","unstructured":"European Association of Urologists Guidelines Office. Prostate cancer. Accessed December 1, 2023. https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"coi240005r49","unstructured":"UK National Screening Committee. Criteria for a population screening programme. Accessed December 1, 2023. https:\/\/www.gov.uk\/government\/publications\/evidence-review-criteria-national-screening-programmes\/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme"},{"key":"coi240005r50","unstructured":"Wilson? JMG, Jungner? G. Principles and practice of screening for disease. Accessed December 1, 2023. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37650\/WHO_PHP_34.pdf?sequence=17&isAllowed=y"},{"key":"coi240005r65","unstructured":"EDRN Prostate MRI Biomarker Study (P-MRI). ClinicalTrials.gov identifier: NCT03784924. Updated February 23, 2024. Accessed December 1, 2023. https:\/\/ClinicalTrials.gov\/show\/NCT03784924"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2817657\/jamaoncology_tosoian_2024_oi_240005_1718739236.69429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:07:53Z","timestamp":1718881673000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2817657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.0455","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.04.11.23288418","asserted-by":"object"}]},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}